Transcriptomics

Dataset Information

0

Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR-gamma activation


ABSTRACT: Tumor metastasis and lack of NKG2D ligand (NKG2DL) expression are associated with poor prognosis in patients with colon cancer. Here we found that spironolactone (SPIR), an FDA-approved diuretic drug with a long-term safety profile, can upregulate NKG2DL expression in multiple colon cancer cell lines by activating the ATM-Chk2-mediated checkpoint pathway, which in turn enhances tumor elimination by natural killer cells. SPIR can also upregulate the expression of metastasis-suppressor genes TIMP2 and TIMP3, thereby reducing tumor cell invasiveness. Although SPIR is an aldosterone antagonist, its anti-tumor effects are independent of the mineralocorticoid receptor pathway. Instead, by screening the human nuclear hormone receptor siRNA library, we identify retinoid X receptor gamma (RXR gamma) as being indispensable for the anti-tumor functions of SPIR. Collectively, our results strongly support the use of SPIR or other RXR gamma-agonists with minimal side effects for colon cancer prevention and therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE50010 | GEO | 2013/10/22

SECONDARY ACCESSION(S): PRJNA215809

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-10-22 | E-GEOD-50010 | biostudies-arrayexpress
2015-07-14 | E-GEOD-70822 | biostudies-arrayexpress
2010-05-26 | E-GEOD-10144 | biostudies-arrayexpress
2021-08-26 | GSE163255 | GEO
2011-04-08 | E-GEOD-28447 | biostudies-arrayexpress
2011-04-08 | GSE28447 | GEO
2015-07-17 | GSE70984 | GEO
2010-10-22 | E-GEOD-24821 | biostudies-arrayexpress
2008-01-12 | GSE10144 | GEO
| PRJNA215809 | ENA